特别药品有限公司将于2026年3月20日启动IPO, Specialty Medicines Ltd. to launch IPO on March 20, 2026, raising ₹29 crore to expand R&D and global reach.

特殊医药有限公司于2026年3月20日推出IPO, 目的是通过在BSE中小企业平台上各发行1 117-124张23.5万卢比的股份, Speciality Medicines Limited is launching an IPO on March 20, 2026, aiming to raise ₹29 crore by issuing 23.5 lakh shares at ₹117–124 each on the BSE SME platform. 收益将为研发、国际产品注册、营销、周转资金和一般开支提供资金。 Proceeds will fund R&D, international product registrations, marketing, working capital, and general expenses. 总部设在孟买的公司侧重于肿瘤学、免疫学和神经学方面的专科药物,在印度20个州和国际市场开展业务。 The company, based in Mumbai, focuses on specialty pharmaceuticals in oncology, immunology, and neurology, with operations across 20 Indian states and international markets. Unistone Capital是图书代理主管,Skyline财务处是登记官。 Unistone Capital is the Book Running Lead Manager, and Skyline Financial Services is the Registrar. IPO被视为扩大其国内和全球足迹的一项战略举措。 The IPO is seen as a strategic move to expand its domestic and global footprint.